GENERIC NEWS:
Hydrocodone Combination Product Rescheduling
Effective October 6, 2014, Hydrocodone Combination Products (HCPs) will be rescheduled from Schedule III to Schedule II. This change is being made by the DEA due to abuse and diversion concerns.
OVERVIEW
Hydrocodone Combination Products (HCPs) will be rescheduled to CII, effective October 6, 2014. This change is being made by the DEA due to abuse and diversion concerns.
Pharmacists should manage their pharmacy handling, storage and ordering ofHCPs carefully as the effective date for rescheduling approaches – particularly if the pharmacy is ineligible to dispense CII controlled substances.
Below please find detailed information regarding important dates to be aware and process and procedures to consider.
WHAT YOU SHOULD DO NEXT
Take action to prepare for the following key dates:
- October 2, 2014:
- Last day to order CIII labeled HCP from McKesson.
- October 3, 2014:
- Last delivery day for CIII labeled HCPs ordered by October 2, 2014.
- Last day for distribution centers to receive CIII labeled HCP returns.
- October 3-5, 2014: Blackout Period; HCP (CII or CIII) unavailable for order.
- October 6, 2014: Effective date for HCP rescheduling to CII
- First day to order CII labeled HCPs.
- As of this date, HCPs distributed by McKesson will be labeled as CII.
- All CII labeled HCPs will have a new McKesson item number.
- All HCP inventory, regardless of labeling, should be managed, stored, handled and dispensed as a CII controlled substance going forward.
- October 7, 2014: First delivery day for CII labeled HCP ordered on October 6, 2014.
Price Assurance Promotion: Price Alert Effective 10/01/14
| Abstract: |
Price assurance will be provided during the price assurance period for the difference between the new invoice price and the invoice price before the invoice price increase, multiplied by the eligible quantity |
| Date: |
10/01/2014 |
The items with future price increases are as follows:
| ITEM NUMBER |
DESCRIPTION |
PRICE PROTECTION START DATE |
PRICE PROTECTION END DATE |
TOP MOVERS* |
|---|
| 1906809 |
MINOCYC HYD CAP 50MG AURO 100@ |
10/1/2014 |
10/31/2014 |
|
| 1906817 |
MINOCYC HYD CAP 75MG AURO 100@ |
10/1/2014 |
10/31/2014 |
|
| 1906023 |
MINOCYCL CAP 100MG AURO 50@ |
10/1/2014 |
10/31/2014 |
|
| 2750297 |
VANCOMY VL 10GM BULK HW1 |
10/1/2014 |
10/31/2014 |
|
| 2737195 |
VANCOMY ADV 1GM HW 10 |
10/1/2014 |
10/31/2014 |
|
| 2732212 |
VANCOMY ADV VL 500MG HW 10 |
10/1/2014 |
10/31/2014 |
|
| 2732162 |
VANCOMY FTV 1GM HW 10 |
10/1/2014 |
10/31/2014 |
|
| 2717486 |
VANCOMY FTV 500MG HW 10 |
10/1/2014 |
10/31/2014 |
|
| 1259969 |
PACLITAX MDV 6MG/ML HW 50ML |
10/1/2014 |
10/31/2014 |
* |
| 1259472 |
PACLITAX MDV 6MG/ML HW 16.7ML |
10/1/2014 |
10/31/2014 |
* |
| 1225598 |
VANCOMY VL 5GM BULK HW 1 |
10/1/2014 |
10/31/2014 |
|
| 1718659 |
ONDANS SDV FT 2MG/ML 2ML HW25 |
10/1/2014 |
10/31/2014 |
|
| 1707736 |
HEPAR SOD 1MU/ML 10ML H/W 25 |
10/1/2014 |
10/31/2014 |
|
| 3601937 |
HEPAR SOD 1MU/ML 1ML H/W 25 |
10/1/2014 |
10/31/2014 |
|
| 1326925 |
CARBOPLAT MDV 10MG/MLMAYN60ML |
10/1/2014 |
10/31/2014 |
|
| 1204874 |
CARBOPLAT MDV 10MG/MLMAYN45ML |
10/1/2014 |
10/31/2014 |
|
You will receive a price assurance payment on purchases of eligible product during the 30-day price assurance period, up to a maximum quantity determined by your purchase history. Price assurance will be provided on the difference between the new invoice price and the invoice price before the invoice price increase, multiplied by the eligible quantity.
Visit the OneStop Generics homepage for the more information about the Price Assurance Promotion.
Note: The percentage increase in the invoice price may vary from the percentage increase in the WAC price.
*Top 250 GCN Rank
Regarding generic Exforge® tablets (amlodipine besylate, valsartan):
To representatives of our valued customers and sales team,
On Tuesday, September 30, Par Pharmaceuticals launched the generic equivalent of Exforge® tablets (amlodipine besylate, valsartan). The Par item will in McKesson Connect on Tuesday, September 30. Inventory is anticipated to be available for purchase on Wednesday, October 1.
Brand Items:
| Item # |
NDC # |
Description |
| 1721620 |
00078048815 |
EXFORGE TAB 5/160MG 30 |
| 1744614 |
00078048915 |
EXFORGE TAB 10/160MG 30 |
| 1721638 |
00078049015 |
EXFORGE TAB 5/320MG 30 |
| 1744622 |
00078049115 |
EXFORGE TAB 10/320MG 30 |
Product Launch Information - OneStop Add
| Bx Name |
Exforge |
| Bx Supplier |
Novartis |
| Generic Name |
amlodipine besylate,valsartan |
| Generic Description |
amlodipine besylate,valsartan
tablets |
| Therapeutic Class/Indication |
242808-DIHYDROPYRIDINES / generic Exforge is indicated for the treatment of hypertension, to lower blood pressure. |
| FDA Approval Date |
October 1, 2014 |
| Launch Reason |
Settlement Agreement |
| Launch Exclusivity |
Yes |
| Number of Players |
1 |
| US Brand Sales |
Estimated annual U.S. brand sales are $437M |
Generic Items:
| Item # |
Supplier Name |
NDC |
Description |
OS Add |
AWP* |
|---|
| 3288156 |
PAR PHARMACEUTICALS |
49884057411 |
AMLO/VALSARTB 5MG/160MGPAR30@ |
9/30/2014 |
Not Available |
| 3288180 |
PAR PHARMACEUTICALS |
49884057511 |
AMLO/VALSARTB 10MG/160MGPAR30@ |
9/30/2014 |
Not Available |
| 3288198 |
PAR PHARMACEUTICALS |
49884057611 |
AMLO/VALSARTB 5MG/320MGPAR30@ |
9/30/2014 |
Not Available |
| 3288206 |
PAR PHARMACEUTICALS |
49884057711 |
AMLO/VALSARTB 10MG/320MGPAR30@ |
9/30/2014 |
Not Available |
*The SWP and/or AWP in this communication was provided by the manufacturer in connection with the launch of this product. McKesson does not take any responsibility for the setting of SWP and/or AWP or the accuracy of this information. AWP will be available in McKesson Connect as and when this information is received from Wolters Kluwer's Medi-Span®.
APCI VENDOR UPDATES:
Clarification on information in last weeks bulletin regarding pricing on Allison Medical Sure Care products: Pricing provided in the 9/29/14 bulletin was estimated NET PRICING based on rebates paid to APCI’s General Fund. This rebate is distributed to members via dividends. We appologize for any confusion this information may have caused. APCI continues to partner with vendors to bring added value to our members. If you have additional quesiton please contact your APCI Representative.
Mallinckrodt update